Recent Finacing
Recent Raise
Equillium is developing EQ504, an oral colon‑targeted aryl hydrocarbon receptor modulator for ulcerative colitis and pouchitis that induces IL‑10/IL‑22 to control inflammation and promote tissue regeneration, entering Phase 1.
